141580-63-4

Upstream product

• 698-63-5 5-nitrofurane-2-carboxaldehyde 
• 141580-54-3 2-[5-(4-fluorophenoxy)-furan-2-yl]-1,1-dibromoethene 
• 33342-17-5 5-(4'-fluorophenyl)furan-2-carbaldehyde 

Downstream Products

• 141580-64-5 4-<5-(4-fluorophenoxy)-2-furyl>-3-butyn-2-ol 
• 169059-37-4 4-(5-(4-fluorophenoxy)-2-furyl)-3-butyn-2-one 
• 141579-87-5 S(-)-A-79176 
• 141579-67-1 A-78773 
• 141598-93-8 N,O-bis(phenoxycarbonyl)-N-<4-<5-(4-fluorophenoxy)-2-furyl>-3-butyn-2-yl>hydroxylamine 
• 1028270-78-1 C₂₇H₁₈FNO₇ 
• 176966-02-2 (R)-N,O-bis(phenoxycarbonyl)-N-{4-[5-(4-fluorophenoxy)-2-furyl]-3-butyn-2-yl}hydroxylamine 
• 141579-87-5 (R)-(+)-N-<3-<5-(4-fluorophenoxy)methyl>-2-furyl>-1-methyl-2-propynyl-N-hydroxyurea 
• 169059-39-6 (S)-4-(5-(4-fluorophenoxy)-2-furyl)-3-butyn-2-ol 

Relevant academic research and scientific papers

Lipoxygenase and cyclooxygenase inhibiting compounds

Compounds having the structure STR1 or a pharmaceutically acceptable salt thereof have activity as inhibitors of cylooxygenase and 5-lipoxygenase, reduce the biosynthesis of leukotrienes B4, C4, D4, and E4 and cylooxygenase products such as prostaglandins and thromboxane and are useful in the treatment of inflammatory and allergic disease states. The compounds have the structure indicated above wherein A is selected from (a) optinally substituted carbocyclic aryl, (b) optinally substituted furyl, (c) optinally substituted benzo[b]furyl, (d) optinally substituted thienyl, (e) optinally substituted pyridyloxy, (f) optinally substituted pyridylalkyl, (g) optinally substituted benzo[b]thienyl, (h) optinally substituted pyridyl, (i) optinally substituted quinolyl, and (j) optinally substituted indolyl; X is selected from (a) optionally substituted alkyl, (b) optinally substituted alkenyl, and (c) optinally substituted alkynyl; R1 and R2 are independently selected from hydrogen, hydroxy, and alkyl; and Z is a residue of a non-steroidal anti-inflammatory drug of the general formula Z--COOH.

(R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]- N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor

Structure-activity optimization of inhibitory potency and duration of action of N-hydroxyurea containing 5-lipoxygenase inhibitors was conducted. The lipophilic heteroaryl template and the link group connecting the template to the N-hydroxyurea pharmacophore were modified. Inhibition of 5- lipoxygenase was evaluated in vitro in a human whole blood assay. An in vitro assay using liver microsomes from monkey was used to evaluate congeners for comparative rates of glucuronidation. (3-Heteroaryl-1-methyl-2-propynyl)-N- hydroxyureas were found to be more resistant to in vitro glucuronidation. The promising inhibitor N-[3-[5-(4-fluorophenoxy)-2-furyl]-1-methyl-2-propynyl]- N-hydroxyurea (6) was found to have stereoselective glucuronidation in monkey and man. The R enantiomer 7 provided longer duration of inhibition as evaluated by an ex vivo whole blood assay. Further optimization of the lipophilic template led to the discovery of (R)-(+)-N-[3-[5-[(4- fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea (11) with more effective and prolonged inhibition of leukotriene biosynthesis than zileuton (1) and 7 in monkey and man. The optimized 5-lipoxygenase inhibitor 11 was selected for development as an investigational drug for leukotriene- mediated disorders.

ACETYLENE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY

Compounds of the structure where p and q are zero or one, but cannot both be the same, M is a pharmaceutically acceptable cation or a metabolically cleavable group, B is a valence bond or a straight or branched alkylene group, R is alkyl, cycloalkyl or --NR1 R2, where R1 and R2 are hydrogen, alkyl, cycloalkyl or alkanoyl, and A is optionally substituted carbocyclic aryl, furyl, benzo[b]furyl, thienyl, or benzo[b]thienyl are potent inhibitors of lipoxygenase enzymes and thus inhibit the biosynthesis of leukotrienes. These compounds are useful in the treatment or amelioration of allergic and inflammatory disease states.